GlassScriptPhysician profile
Vandana Jain
NPI 1730143728
$13,307.53
in general payments reported to CMS, 2019-2025
64 companies · $1,736 in 2025
The $1,736 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,172 · 2020: $1,381 · 2021: $1,724 · 2022: $1,810 · 2023: $2,144 · 2024: $2,342 · 2025: $1,736.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,189 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,188.90 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,296.53 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $1,592.67 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,466.51 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $1,177.31 | 2019-2025 | |
| Amgen INC. | $893.98 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $732.95 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Merck Sharp & Dohme LLC | $584.79 | 2019-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Glaxosmithkline, LLC. | $342.03 | 2020-2025 | Shingrix, Arexvy |
| Astellas Pharma US INC | $318.83 | 2019-2023 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $313.71 | 2020-2025 | Spravato, Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $306.24 | 2019-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $268.96 | 2019-2025 | Jardiance, Ofev |
| Abbott Laboratories | $247.36 | 2019-2022 | |
| Esperion Therapeutics, INC. | $188.17 | 2021-2025 | Nexletol |
| Novartis Pharmaceuticals Corporation | $152.25 | 2019-2025 |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vandana Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.